H.I.G. Capital News
May 22, 2013 - Cardeas Pharma Completes $34 Million in Series B Financing
SEATTLE - May 22, 2013 - Cardeas Pharma Corporation, a biopharmaceutical company focused on the development of innovative therapies for the treatment of multi-drug resistant (MDR) bacterial infections, announced today the completion of a $34 million Series B round of financing. The…
May 1, 2013 - Novadaq Announces the Sale of US$50.3 Million of Common Shares
TORONTO, ONTARIO - May 1, 2013 - Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical and outpatient wound care procedures, announced today the sale of US$50.3…
BOTHELL, WASH. and VANCOUVER, BRITISH COLUMBIA - May 1, 2013 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Rainier™ trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with…
April 23, 2013 - Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement
RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO - April 23, 2013 - Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics, and Ocera Therapeutics, Inc. ("Ocera"), a privately held…
April 2, 2013 - Apollo Endosurgery’s OverStitch™ Endoscopic Suturing Platform Launches in Europe
AUSTIN, TX - April 2, 2013 – Apollo Endosurgery, Inc., a company focused on the development of devices that enable a new generation of endoscopic surgical procedures, announced that its OverStitch™ Endoscopic Suturing System has received the European Union’s CE Mark. The company…
BOTHELL, WA – March 20, 2013 – Alder Biopharmaceuticals Inc. today announced the dosing of the first patients in a proof-of-concept Phase 2 clinical study of its antibody therapeutic candidate, ALD403, targeting calcitonin gene-related peptide (CGRP) for treatment of migraine. The…
BOTHELL, WASHINGTON and VANCOUVER, BRITISH COLUMBIA - March 7, 2013 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today highlighted key clinical development activities for its two product candidates, custirsen and OGX-427, and announced its fourth quarter and year end 2012 financial…
February 8, 2013 - Tranzyme Pharma Announces Exploration of Strategic Alternatives
RESEARCH TRIANGLE PARK, N.C. - February 8, 2013 - Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other…
February 7, 2013 - Novadaq Reports 2012 Fourth Quarter and Full Year Financial Results
TORONTO, ONTARIO — February 7, 2013 – Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ,), a developer of clinically-relevant fluorescence imaging solutions for use in surgical procedures, today announced financial…
Research Triangle Park, N.C. - January 4, 2013 – Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule macrocyclic compounds, today announced the successful completion of its chemistry-based drug discovery…